SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Obstetric and Pediatric Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1621101
Trade-offs from a Family Perspective: Considerations in Choosing Between Omalizumab and Complementary Alternative Medicine for Pediatric Severe Asthma
Provisionally accepted- 1School of Pediatric Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, China
- 2Chongqing Hospital Of Traditional Chinese Medicine, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The management of pediatric severe asthma poses significant challenges for families. When faced with the choice between targeted biologics like omalizumab and widely used complementary alternative medicine (CAM), families navigate a complex decision-making process influenced by multiple factors. This review adopts a family-centered perspective to systematically analyze key factors influencing this trade-off: treatment goals (extending beyond clinical metrics to focus on quality of life), risk perception (shaped by subjective constructs and lacking direct evidence for comparative risk assessments), treatment burden (often overlooked hidden costs), and the current state of shared decision-making (SDM). Analysis reveals that family decision-making is a multidimensional construct shaped by four core elements: value systems, lived experiences, risk perception patterns, and tolerance for treatment burden. Notably, the significant gap in risk perception evidence leads to subjective risk assessments dominating decisions, particularly in CAM choices. Treatment burden, a critical hidden cost, is often marginalized in decisions, hindering effective SDM. Health equity further profoundly impacts choices.The conclusion emphasizes the need for clinical practice to shift toward family-centered care by addressing real-world needs, routinely evaluating treatment burden, optimizing risk communication, overcoming SDM barriers, and promoting health equity. Future research must fill evidence gaps in risk perception, develop SDM tools, and address culturally diverse family needs.
Keywords: Pediatric severe asthma, Family perspective, Omalizumab, Complementary Alternative Medicine (CAM), Treatment Decision-making, Risk Perception, treatment burden, Shared decision-making (SDM)
Received: 30 Apr 2025; Accepted: 10 Jun 2025.
Copyright: © 2025 CHEN, Xu, Qiu, Guan, Cui, Wei, Zhang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yan Xu, School of Pediatric Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.